Compare NOTV & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOTV | RFL |
|---|---|---|
| Founded | 1974 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 61.1M |
| IPO Year | 1997 | 2017 |
| Metric | NOTV | RFL |
|---|---|---|
| Price | $0.40 | $1.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 575.0K | 91.0K |
| Earning Date | 05-14-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.64 | 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $547,656,000.00 | $917,000.00 |
| Revenue This Year | $5.28 | N/A |
| Revenue Next Year | $5.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 511.19 | 43.96 |
| 52 Week Low | $0.25 | $1.12 |
| 52 Week High | $3.35 | $3.19 |
| Indicator | NOTV | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 65.63 |
| Support Level | $0.26 | $1.41 |
| Resistance Level | $0.65 | $1.63 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 70.04 | 71.25 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.